FDA Set To Back Peptide Drugs, Putting Hims & Hers (NYSE: HIMS) And Novo Nordisk (NYSE: NVO) In Focus
Peptides, short-chain amino acids formulated into pharmaceutical compounds, are drawing fresh regulatory attention from the Trump administration’s Food and Drug Administration. The most widely…
Read the full articleYou might also wanna read
Croatian researchers thrust into limelight as their 1990s’ peptide discovery goes mainstream in the US
Trump administration hopes to approve peptides popular with MAHA wellbeing advocates. How are the researchers at the centre of this coping w
Peptides, Aging, and Chronic Health: What You Need to Know Before Following the Trend
Peptides are drawing attention for weight loss, metabolism, and healthy aging. While some FDA-approved peptide drugs help treat obesity and
Compounded peptides placed on restrictive list by FDA, lawsuit filed
The FDA is evaluating the future of compounded peptides, which are popular short-chain amino acids that signal cells to perform specific bio
The unregulated peptide boom: Americans risk unknown side effects for quick-fix weight loss and anti-aging drugs
Across the US, thousands of people are injecting themselves with unregulated peptides in pursuit of weight loss, muscle growth and younger-l
theguardian.com·23d ago
Pharmaceutical industry embraces cyclic peptides as FDA fast-tracks Merck's candidate
In this Eye on Patents column, we explore the pharmaceutical industry’s embrace of these circular molecules
cen.acs.org·1mo ago
Pharmaceutical industry embraces cyclic peptides as FDA fast-tracks Merck candidate
In this Eye on Patents column, we explore the pharmaceutical industry’s embrace of these circular molecules
cen.acs.org·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.